Mark Zuckerberg and Priscilla Chan’s Biohub unveiled a large‑scale initiative to merge frontier AI with experimental biology and announced the integration of EvolutionaryScale’s team — the creators of large models for biology — to accelerate datasets, compute and modeling for disease prevention and cure. The combined organization plans to scale compute to thousands of GPUs and unite experimentalists, AI researchers and instrumentation. Biohub framed the move as building 'frontier‑level' capabilities—instrumentation, imaging, compute and integrated teams—to push AI‑driven biology from discovery to translational impact. EvolutionaryScale cofounder Alex Rives will serve as head of science in the merged effort. The step signals continued convergence of big‑tech capital, large compute investments, and academic translational partnerships; biotech players will watch for partnerships, data‑sharing models, and how governance, IP and compute access are structured as the initiative ramps.